纳米功能材料在血栓诊疗领域的研究进展  

Research Progress of Functional Nanomaterials in Thrombus Diagnosis and Treatment

作　　者：李博 杨童 刘锦 蒋鹏 周倩 LI Bo;YANG Tong;LIU Jin;JIANG Peng;ZHOU Qian(Institute of Chinese Medicinal Sciences,Guangdong Pharmaceutical University,Guangzhou 510006,China;College of Life Science and Technology,Jinan University,Guangzhou 510632,China;Institute of Blood Transfusion,Chinese Academy of Medical Sciences,Chengdu 610052,China)

机构地区：[1]广东药科大学中医药研究院,广州510006 [2]暨南大学生命科学学院,广州510632 [3]中国医学科学院输血研究所,成都610052

出　　处：《医学综述》2022年第4期730-735,共6页Medical Recapitulate

基　　金：国家自然科学基金(31801192)。

摘　　要：血栓性疾病具有潜伏期长、发病突然、致死率高的特点,严重威胁人们的生命健康。血栓病灶的早期诊断及有效溶栓是决定治疗效果的关键因素。然而,现阶段临床影像学技术尚无法识别急性新发血栓,极易误诊而延误治疗时机;且临床溶栓治疗主要利用纤溶酶原激活剂(PA)实现,但PA治疗窗口期短、体内清除迅速,存在引发颅内出血的风险。基于纳米技术的靶向递送系统已成为血栓诊疗领域的新兴技术之一,针对血栓生物标志物设计开发的靶向纳米体系是实现血栓早期诊断及溶栓治疗的研究热点。Thrombotic diseases have the characteristics of longer latency,rapid onset,and high mortality,which seriously threaten the life and health of the people.Early diagnosis and effective thrombolysis are the key factors influencing the therapeutic effect.However,the current clinical imaging technology couldn′t detect acute new thrombosis,which is easy to result in misdiagnosis and delaying treatment opportunity.What′s more,plasminogen activators(PA)is mainly used in the clinical thrombolytic therapy,but PA has a short treatment window and rapid clearance in vivo,which has the risk of intracranial hemorrhage.Nanotechnology-based targeted delivery systems have become one of the most emerging technologies in the field of thrombus diagnosis and treatment,and the targeted nano system designed and developed for thrombus biomarkers is a research hotspot to realize early diagnosis and thrombolytic therapy of thrombus.

关 键 词：血栓性疾病 早期诊断 溶栓治疗 靶向递送 纳米材料 

分 类 号：R543[医药卫生—心血管疾病]